Ryanodine Receptor as a New Therapeutic Target of Heart Failure and Lethal Arrhythmia

DOI Web Site 7 Citations 110 References
  • Yano Masafumi
    Department of Medicine and Clinical Science, Division of Cardiology, Yamaguchi University Graduate School of Medicine

Search this article

Abstract

Abnormal intracellular Ca2+ handling by the sarcoplasmic reticulum (SR) is a critical factor in the development of heart failure (HF). Not only decreased Ca2+ uptake, but also uncoordinated Ca2+ release plays a significant role in contractile and relaxation dysfunction. Spontaneous Ca2+ release through ryanodine receptor (RyR) 2, a huge tetrameric protein, during diastole leads to a decrease in the SR Ca2+ content, and also triggers delayed afterdepolarization that is a substrate for lethal arrhythmia. Several disease-linked mutations of RyR have been reported in patients with catecholaminergic polymorphic ventricular tachycardia (CPVT) or arrhythmogenic right ventricular cardiomyopathy type 2 (ARVC2). The unique distribution of these mutation sites has lead to the concept that an interaction among the putative regulatory domains within RyR may play a key role in regulating channel opening, and that there seems to be a common abnormality in the channel disorder of HF and CPVT/ARVC2. Recent knowledge gained from pathological conditions may lead to the development of a new therapeutic strategy for the treatment of HF or cardiac arrhythmia. (Circ J 2008; 72: 509 - 514)<br>

Journal

  • Circulation Journal

    Circulation Journal 72 (4), 509-514, 2007

    The Japanese Circulation Society

Citations (7)*help

See more

References(110)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top